Is Neovacs SA halal to invest in?

According to Musaffa's Shariah screening methodology, Neovacs SA (ALNEV.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Neovacs SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neovacs SA using these criteria to determine its compliance status.

Can Muslims buy shares of Neovacs SA?

Muslim investors may consider investing in Neovacs SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Neovacs SA classified as NOT HALAL?

Musaffa determines the Shariah status of Neovacs SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Neovacs SA updated?

The Shariah compliance status of Neovacs SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Neovacs SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Neovacs SA?

You can check the latest Shariah compliance status of Neovacs SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Neovacs SA ALNEV.PA

€0.00

Last Updated: May 15, 12:00 AM·XPAR

ALNEV.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 28, 2025

Report Source: 2024 Annual Report

Neovacs SA. Stock Analysis ALNEV.PA

France Health Care Nano Cap Report: 2024 Annual

Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Suresnes, Ile-De-France and currently employs 16 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.

Key Statistics of Neovacs SA (ALNEV.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.00€0.00

Today's Open

€0.00

Volume

1.79M

P/E Ratio (TTM)

52 Week Range

€0.00€6.60

Market Cap

98.08K

Avg. Volume

14.87M

Dividend Yield

Financial Metrics & Statements of Neovacs SA (ALNEV.PA)

FAQ's for Neovacs SA (ALNEV.PA)

According to Musaffa’s Shariah screening methodology, Neovacs SA (ALNEV.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.